Publications

1. Tolvaptan (Jinarc ®) for the treatment of chronic kidney disease - alteration of the specific conditions

   The National Health Care Institute carried out an assessment whether the specific conditions for tolvaptan (Jinarc ®) can be ...

   Report | 02-04-2019

2. Durvalumab (Imfinzi®) for the treatment of locally advanced, unresectable, non-small cell lung cancer

   The National Health Care Institute has completed its assessment of durvalumab (Imfinzi®) as monotherapy for the treatment of ...

   Report | 01-04-2019

3. Amendment of the conditional inclusion of the medicine Fingolimod (Gilenya®) for the treatment of relapsing remitting multiple sclerosis (RRMS)

   Zorginstituut Nederland carried out an assessment in relation to extending the specific conditions for the medicinal  product ...

   Report | 25-03-2019

4. Abemaciclib (Verzenios®) for the treatment of metastatic breast cancer

   The National Health Care Institute has completed its assessment of abemaciclib (Verzenios®) for the treatment of metastatic ...

   Report | 07-03-2019

5. Axicabtagene ciloleucel (Yescarta®) for the treatment of adult patients with recurring or refractory diffuse large-cell B-cell lymphoma (DLBCL) and primary mediastinal large-cell B-cell lymphoma (PMBCL)

   The National Health Care Institute carried out an assessment of the medicinal product axicabtagene ciloleucel (axi-cel, ...

   Report | 07-03-2019

6. Tisagenlecleucel (Kymriah®) for the treatment of DLBCL

   The National Health Care Institute has completed its assessment of tisagenlecleucel (Kymriah®) for the treatment of DLBCL. Due to ...

   Report | 07-03-2019

7. Rivaroxaban (Xarelto®) for the prevention of atherothrombotic complications in adult patients with coronary artery disease

   The National Health Care Institute carried out an assessment of medicinal product rivaroxaban (Xarelto®). The manufacturer ...

   Report | 04-03-2019

8. Patiromer (Veltassa®) for the treatment of hyperkalaemia in adults

   The National Health Care Institute has carried out an assessment whether patiromer (Veltassa®) is interchangeable with a ...

   Report | 25-02-2019

9. GVS assessment of evolocumab (Repatha®) for the treatment of primary hypercholesterolaemia

   The National Health Care Institute carried out a reassessment of the medicinal product Evolocumab (Repatha®) for the treatment of ...

   Report | 23-01-2019

10. Tisagenlecleucel-T (Kymriah®) for the treatment of ALL

    The National Health Care Institute carried out an assessment of the medicinal product tisagenlecleucel-T (Kymriah®) for the ...

    Report | 18-12-2018